HCM
CARM

Highbridge Capital Management’s Carisma Therapeutics CARM Stock Holding History

Highbridge Capital Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-79,681
Closed -$1.67M – 959
2018
Q1 		$1.67M Buy
+79,681
New +$1.53M 0.03% 458

Other funds holding CARM

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CHP
Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return

Highbridge Capital Management's CARM Position: Q2 2018 in Review

Highbridge Capital Management sold out of Carisma Therapeutics (CARM) in Q2 2018, closing a stake of 79,681 shares — an estimated $1.67M sold.

Highbridge Capital Management first reported a position in CARM in Q1 2018 and held it in 1 quarter. The position peaked at $1.67M in Q1 2018. 46 funds tracked by Wall St. Rank hold CARM as of Q2 2018.

  • Highbridge Capital Management reported no remaining Carisma Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Highbridge Capital Management sold 79,681 Carisma Therapeutics shares in Q2 2018, an estimated $1.67M.
  • Highbridge Capital Management first reported a position in Carisma Therapeutics in Q1 2018 and held it in 1 quarter.
  • Highbridge Capital Management's Carisma Therapeutics position peaked at $1.67M in Q1 2018.
  • 46 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2018.

Based on Highbridge Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.